News
ESALF
29.00
NaN%
--
Weekly Report: what happened at ESALF last week (0831-0904)?
Weekly Report · 2d ago
Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results
TipRanks · 6d ago
Weekly Report: what happened at ESALF last week (0824-0828)?
Weekly Report · 08/31 10:18
GSK: Still One Of My Top Healthcare Picks
Seeking Alpha · 08/27 12:08
Weekly Report: what happened at ESALF last week (0817-0821)?
Weekly Report · 08/24 10:19
Eisai’s E2086 Metabolism Study Clears a Key Early Milestone for Investors
TipRanks · 08/21 16:31
Lenvatinib Combo Falls Short in Esophageal Cancer: What Eisai Investors Need to Know
TipRanks · 08/21 16:30
Weekly Report: what happened at ESALF last week (0810-0814)?
Weekly Report · 08/17 10:20
Eisai’s E2086 Drug-Interaction Study Sets Up Long-Term Pipeline Potential
TipRanks · 08/14 16:30
Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s
Seeking Alpha · 08/14 12:31
Eisai’s New LEQEMBI Registry: Real World Safety Data That Could Shape Alzheimer’s Drug Markets
TipRanks · 08/13 16:32
Weekly Report: what happened at ESALF last week (0803-0807)?
Weekly Report · 08/10 10:15
Weekly Report: what happened at ESALF last week (0727-0731)?
Weekly Report · 08/03 10:15
Eisai GAAP EPS of ¥64.71, revenue of ¥234.3B; updates FY 2026 outlook
Seeking Alpha · 08/03 07:23
Eisai Earnings Call Highlights LEQEMBI-Driven Surge
TipRanks · 08/03 00:02
Biogen raises revenue outlook as growth portfolio drives Q2 beat
Seeking Alpha · 07/29 11:05
ProMIS jumps after early-stage trial data for Alzheimer’s therapy
Seeking Alpha · 07/28 17:55
Weekly Report: what happened at ESALF last week (0720-0724)?
Weekly Report · 07/27 10:19
Weekly Report: what happened at ESALF last week (0713-0717)?
Weekly Report · 07/20 10:15
Eisai’s E7090 Breast Cancer Trial Reaches Key Milestone, Setting Up Next Investor Catalyst
TipRanks · 07/17 16:30
More
Webull provides a variety of real-time ESALF stock news. You can receive the latest news about Eisai Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ESALF
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.